Sponsors

Cost-effective cytomegalovirus native antigen

The Native Antigen Company (NAC) has released a highly purified cytomegalovirus (CMV) native antigen, which has been manufactured in response to the in vitro diagnostics (IVD) industry’s requirement for a cost-effective antigen that can demonstrate a high affinity for IgG and IgM. This latest antigen from NAC’s rapidly increasing portfolio also minimises cross-reactivity and lot-to-lot variation.

Presently, CMV infection is mostly controlled in immunocompromised patients by available antiviral drugs, yet it continues to maintain its role as one of the most dangerous infectious agents to the unborn infant. Primary infection is consistently associated with the presence of a virus-specific IgM antibody response. Use of NAC’s CMV purified native antigen will aid in improving serology-based assays for early detection.

www.thenativeantigencompany.com

Latest Issues

RSM / Path Soc 2026 Winter Meeting

The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE
20 - 21 January, 2026

BIVDA Regulatory Affairs Seminar

Grand Hotel, Birmingham
10 - 11 February, 2026

BDIAP Molecular Pathology Study Day

10 Union Street, London, SE1 1SZ
2 March, 2026

USCAP 115th Annual Meeting

Henry B. González Convention Center, San Antonio, Texas, USA
21 - 26 March, 2026